As­traZeneca nabs 6 more months for Sym­bi­cort patent in lat­est court rul­ing

A fed­er­al judge in West Vir­ginia ruled in fa­vor of As­traZeneca on Wednes­day, adding six months of patent pro­tec­tion for its asth­ma and COPD in­haler block­buster Sym­bi­cort.

The lat­est rul­ing con­cerns a rel­a­tive­ly new patent pro­tec­tion that As­traZeneca had ob­tained ear­li­er this year. The new judge­ment on that case rules that My­lan (now Vi­a­tris) and Kinde­va Drug De­liv­ery in­fringed on five claims of that ‘588 patent.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER